
    
      The subjects were classified into two subtypes (type 1 and type 2 polypoidal choroidal
      vasculopathy) based on the presence or the absence of both of a feeder and a draining vessels
      on indocyanine green angiography. All received intravitreal injection of aflibercept (2.0 mg)
      at baseline and months 1, 2 and 4.
    
  